FDA Approves Otsuka & Lundbeck’s Rexulti

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced that the U.S. Food and Drug Administration (FDA) approved Rexulti (brexpiprazole) as an adjunctive therapy for the treatment of adults with major depressive disorder (MDD) and as a treatment for adults with schizophrenia. Rexulti was discovered by Otsuka and co-developed with Lundbeck. It will be co-marketed by the two companies and is expected to become available to patients in the U.S. in early August 2015. Rexulti is a dopamine D2 and serotonin 5-HT1A partial agonist positioned as a successor to Otsuka's atypical antipsychotic Abilify . . .